Results 41 to 50 of about 39,319 (333)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [PDF]
, 2016 Background: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess Balasubramanian, Sriram, Bandyopadhyay, Nibedita, Bence-Bruckler, Isabelle, Bothos, John, Caballero, Dolores, Cho, Seok-Goo, Dreyling, Martin, Enny, Christopher, Goldberg, Jenna D, Hess, Georg, Jerkeman, Mats,, Joao, Cristina, Jurczak, Wojciech, Lund University., Lund University., Offner, Fritz, Rizo, Aleksandra, Rule, Simon, Rusconi, Chiara, Silva, Rodrigo Santucci, Sun, Steven, Traina, Shana, Trneny, Marek, Vermeulen, Jessica, Witzens-Harig, Mathias +24 morecore +1 more sourceExtended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Blood, 2023
Introduction: ALPINE, a randomized, multinational phase 3 study (NCT03734016) in patients with R/R CLL/SLL, established the statistical and clinically meaningful superiority of zanubrutinib over ibrutinib on progression-free survival (PFS) and overall ...Jennifer R. Brown, B. Eichhorst, N. Lamanna, S. O'Brien, Constantine S. Tam, Luqui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, K. Zhou, M. Šimkovič, Jiří Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. Ganly, R. Weinkove, S. Grosicki, A. Mital, Tadeusz Robak, A. Osterborg, H. Yimer, M. Wang, T. Salmi, Liping Wang, Jessica Li, Kenneth Wu, A. Cohen, M. Shadman +26 moresemanticscholar +1 more sourceIdentification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]
, 2014 Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva +59 morecore +1 more sourceClinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
Blood Advances, 2023 Key Points • In the PHOENIX trial, the addition of ibrutinib to R-CHOP did not improve the survival of patients with previously untreated non-GCB DLBCL.• This study identified a patient subset with high BCL2/MYC coexpression using RNA sequencing, with ...P. Johnson, S. Balasubramanian, B. Hodkinson, S. Shreeve, Steven Sun, Srimathi Srinivasan, A. Steele, J. Vermeulen, L. Sehn, W. Wilson +9 moresemanticscholar +1 more sourceIbrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]
, 2017 Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee +41 morecore +2 more sourcesPhase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
Blood Advances, 2023 Key Points • SELENE is a phase 3, placebo-controlled trial evaluating ibrutinib or placebo added to BR/R-CHOP for patients with R/R FL or MZL.• The addition of ibrutinib to BR or R-CHOP did not significantly improve the PFS.L. Nastoupil, G. Hess, M. Pavlovsky, I. Danielewicz, Jane A Freeman, A. M. Martin Garcia-Sancho, Valeria Glazunova, Andrew A Grigg, Jing-Zhou Hou, A. Janssens, Seok-Jin Kim, Z. Masliak, P. McKay, F. Merli, W. Munakata, H. Nagai, M. Özcan, M. Preis, Tingyu Wang, Melissa Rowe, M. Tamegnon, Rui Qin, T. Henninger, M. Curtis, D. B. Caces, C. Thieblemont, G. Salles +26 moresemanticscholar +1 more sourceTargeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]
, 2016 Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea +7 morecore +1 more sourceAbsence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Clinical Cancer Research, 2023 Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment.Nitin Jain, Lisa J Croner, J. Allan, Tanya Siddiqi, A. Tedeschi, X. Badoux, K. Eckert, L. Cheung, Anwesha Mukherjee, J. P. Dean, E. Szafer-Glusman, J. F. Seymour +11 moresemanticscholar +1 more sourceModulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Journal for ImmunoTherapy of Cancer, 2023 Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.Li Zhang, Matthew Crocker, Lawrence Fong, Lisa M Coussens, Charles D Lopez, Shamilene Sivagnanam, Meenal Sinha, Brandon Chen, Jaqueline Marquez, Alexander Cheung, Whitney Tamaki, Jacob Stultz, Kendra Todd, Courtney Betts, Madeline J Griffith, Isabelle Solman, Eric Liu, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Margaret Tempero +28 moredoaj +1 more source
